Janet H. Scott

2.4k total citations · 1 hit paper
49 papers, 1.9k citations indexed

About

Janet H. Scott is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Janet H. Scott has authored 49 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Janet H. Scott's work include Cancer Cells and Metastasis (14 papers), Cancer Genomics and Diagnostics (12 papers) and Metastasis and carcinoma case studies (5 papers). Janet H. Scott is often cited by papers focused on Cancer Cells and Metastasis (14 papers), Cancer Genomics and Diagnostics (12 papers) and Metastasis and carcinoma case studies (5 papers). Janet H. Scott collaborates with scholars based in United States, United Kingdom and Switzerland. Janet H. Scott's co-authors include Randy Schekman, Harvey B. Pollard, John W. Park, R. Nicol, Carl E. Creutz, Mark Jesus M. Magbanua, Christopher J. Pazoles, Hope S. Rugo, David Wofsy and William E. Seaman and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Janet H. Scott

49 papers receiving 1.9k citations

Hit Papers

Lyticase: Endoglucanase and Protease Activities That Act ... 1980 2026 1995 2010 1980 50 100 150 200 250

Peers

Janet H. Scott
Andrea Sacchetti Netherlands
A Nicolin Italy
Hyuk‐Jin Cha South Korea
Ekrem Emrah Er United States
Andrea Sacchetti Netherlands
Janet H. Scott
Citations per year, relative to Janet H. Scott Janet H. Scott (= 1×) peers Andrea Sacchetti

Countries citing papers authored by Janet H. Scott

Since Specialization
Citations

This map shows the geographic impact of Janet H. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet H. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet H. Scott more than expected).

Fields of papers citing papers by Janet H. Scott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet H. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet H. Scott. The network helps show where Janet H. Scott may publish in the future.

Co-authorship network of co-authors of Janet H. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Janet H. Scott. A scholar is included among the top collaborators of Janet H. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet H. Scott. Janet H. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Magbanua, Mark Jesus M., Oleksandr Savenkov, Erik Asmus, et al.. (2020). Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clinical Cancer Research. 26(18). 4911–4920. 19 indexed citations
2.
Magbanua, Mark Jesus M., Christina Yau, Denise M. Wolf, et al.. (2019). Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. Clinical Cancer Research. 25(17). 5388–5397. 21 indexed citations
3.
Magbanua, Mark Jesus M., Hope S. Rugo, Denise M. Wolf, et al.. (2018). Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clinical Cancer Research. 24(6). 1486–1499. 36 indexed citations
4.
Lee, Jin Sun, Michelle Melisko, Mark Jesus M. Magbanua, et al.. (2015). Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Research and Treatment. 154(2). 339–349. 55 indexed citations
5.
Magbanua, Mark Jesus M., Lisa A. Carey, Amy DeLuca, et al.. (2014). Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research. 21(5). 1098–1105. 32 indexed citations
6.
Lang, Julie E., Janet H. Scott, Denise M. Wolf, et al.. (2014). Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 121–131. 42 indexed citations
7.
Magbanua, Mark Jesus M., Michelle Melisko, Ritu Roy, et al.. (2013). Molecular Profiling of Tumor Cells in Cerebrospinal Fluid and Matched Primary Tumors from Metastatic Breast Cancer Patients with Leptomeningeal Carcinomatosis. Cancer Research. 73(23). 7134–7143. 52 indexed citations
8.
Magbanua, Mark Jesus M., Eduardo V. Sosa, Ritu Roy, et al.. (2012). Genomic Profiling of Isolated Circulating Tumor Cells from Metastatic Breast Cancer Patients. Cancer Research. 73(1). 30–40. 78 indexed citations
9.
Ko, Andrew H., Alan P. Venook, Emily K. Bergsland, et al.. (2010). A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. 66(6). 1051–1057. 66 indexed citations
10.
Lang, Julie E., Mark Jesus M. Magbanua, Janet H. Scott, et al.. (2009). A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics. 10(1). 326–326. 23 indexed citations
11.
Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2008). A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?. Investigational New Drugs. 26(5). 463–471. 55 indexed citations
12.
García, Jorge A., Jonathan E. Rosenberg, Vivian Weinberg, et al.. (2007). Evaluation and significance of circulating epithelial cells in patients with hormone‐refractory prostate cancer. British Journal of Urology. 99(3). 519–524. 35 indexed citations
13.
Rini, Brian I., Vivian Weinberg, Vanessa Shaw, et al.. (2004). Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN‐01, in renal cell carcinoma. Cancer. 101(1). 90–95. 13 indexed citations
14.
Powell, C. Bethan, Janet H. Scott, & John Leslie Collins. (1998). Comparison of TNFα and TNFβ Cytolytic Mechanisms in Human Ovarian and Cervical Carcinoma Cell Lines. Gynecologic Oncology. 71(2). 258–265. 11 indexed citations
15.
Scott, Janet H., et al.. (1996). Characterization of the Protein Synthesis Independent TNFα Lytic Mechanism in Human Ovarian and Cervical Carcinoma Cell Lines. Gynecologic Oncology. 62(1). 42–48. 7 indexed citations
16.
Powell, C. Bethan, Thomas J. Herzog, Janet H. Scott, & John Leslie Collins. (1995). Evidence for a Protein Synthesis-Dependent and -Independent TNFα Cytolytic Mechanism. Gynecologic Oncology. 58(3). 327–335. 10 indexed citations
17.
Nicol, R. & Janet H. Scott. (1986). Lytic Spondylolysis. Spine. 11(10). 1027–1030. 119 indexed citations
18.
Pollard, Harvey B., Carl E. Creutz, Velia M. Fowler, Janet H. Scott, & Christopher J. Pazoles. (1982). Calcium-dependent Regulation of Chromaffin Granule Movement, Membrane Contact, and Fusion during Exocytosis. Cold Spring Harbor Symposia on Quantitative Biology. 46(0). 819–834. 47 indexed citations
19.
Pollard, Harvey B. & Janet H. Scott. (1982). Synhibin: A new calcium‐dependent membrane‐binding protein that inhibits synexin‐induced chromaffin granule aggregation and fusion. FEBS Letters. 150(1). 201–206. 29 indexed citations
20.
Scott, Janet H.. (1956). Assessment of Ununited Fractures of the Carpal Scaphoid. Proceedings of the Royal Society of Medicine. 49(11). 961–962. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026